Adeptus Health Inc. (NYSE:ADPT) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On April 21, 2017 Adeptus Health Inc. (“the Company”) was notified by the New York Stock Exchange (the “NYSE”) that the NYSE has decided that the Company is no longer suitable for listing to Section 802.01D of the NYSE Listed Company Manual and has determined to commence proceedings to delist the Company’s Class A common stock. In its notification letter to the Company, the NYSE stated that its decision is because of the Company’s announcement on April 19, 2017 that it and certain of its subsidiaries have filed petitions for relief under chapter 11 of the U.S. Bankruptcy Code in the U.S. District Court for the Northern District of Texas, Dallas Division. Trading in the Company’s Class A common stock was suspended immediately after the market closed on April 19, 2017.
The Company has a right to review this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission (the “SEC”) to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision. The Company does not intend to appeal the determination and, therefore, it is expected the Company’s common stock will be delisted. Effective April 20, 2017, the Class A common stock of the Company commenced trading on the OTC Pink marketplace under the symbol ADPTQ. The Company can provide no assurance that its Class A common stock will continue to trade on this market, whether broker-dealers will continue to provide public quotes of the Company’s Class A common stock on this market, whether the trading volume of the Company’s Class A common stock will be sufficient to provide for an efficient trading market or whether quotes for the Company’s Class A common stock may be blocked by OTC Markets Group in the future.